Journal of pain and symptom management 2017 07 12() pii S0885-3924(17)30274-9
Breakthrough cancer pain (BTcP) has not been properly evaluated and treated because there are relatively few available measurements. The breakthrough pain assessment tool (BAT) is currently recognized as a brief, multidimensional, and reliable measurement.
To validate the Korean version of the BAT (BAT-K) in adult cancer patients METHODS: We conducted a forward-backward translation and cross-cultural equivalence test. The psychometric properties with 120 cancer patients were assessed using factor analysis, reliability, and validity.
The Korean translation was well accepted by participants. Factor analysis revealed the presence of two underlying factors: frequency/severity and duration/medication efficacy. Cronbach’s alpha coefficient was 0.743. Severity, distress, and disruption of normal life showed strong reliability. The intra-class correlation for the test-retest reliability was 0.782 (95% confidence interval: 0.694-0.854). The BAT-K had significant correlations with the Brief Pain Inventory, Pain Management Index and Eastern Cooperative Oncology Group performance status (all Ps < 0.05). CONCLUSION
The BAT-K is a valid and reliable measurement of BTcP in Korean cancer patients.